Navigation Links
Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
Date:9/26/2007

ROCKVILLE, Md., Sept. 26 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company's Board of Directors. With more than 20 years of experience in product development and commercialization in the pharmaceutical and biotechnology industry, Mr. Buchalter is well poised to work with the management team at MacroGenics as the company matures toward commercializing its pipeline.

"We are honored that Mr. Buchalter, an established leader in the biotechnology and pharmaceutical industry, has joined the MacroGenics Board of Directors as Chairman. His proven skills in building and transitioning research and development-based organizations into commercial enterprises will be a tremendous asset to MacroGenics," commented Scott Koenig, M.D., Ph.D., President and CEO.

"I am excited to have an opportunity to work closely with such a talented management team and esteemed group of investors and directors at MacroGenics," said Mr. Buchalter. "The company has done a terrific job in creating one of the best programs in monoclonal antibody therapeutics with its rich pipeline, platforms, and product development capabilities."

Mr. Buchalter currently serves as President, CEO and Chairman of the Board of Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN), a biopharmaceutical company dedicated to the development and commercialization of therapeutics for cancer and other life-threatening diseases. Prior to joining Enzon, Mr. Buchalter was President and Chief Executive Officer of ILEX Oncology, Inc., where he led the company's evolution from a contract research organization to a product- driven pharmaceutical company, with a high quality oncology franchise and established commercialization expertise. During Mr. Buchalter's tenure at ILEX, the company was acquired by Genzyme Corporation for $1.1 billion.

Mr. Buchalter also has held leadership roles at Pharmacia Corporation, Wyeth and Schering-Plough Corporation and has received awards for his commitment to the field of cancer research and development. In particular, he received the American Cancer Society's Joseph F. Buckley Memorial Award and was invited by former President George Bush to serve as a collaborating partner in the National Dialogue on Cancer. Mr. Buchalter received his B.S. in finance from Seton Hall University and a MBA in marketing from Temple University.

About MacroGenics, Inc.

Founded in 2000, MacroGenics is a private, venture-backed biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer and infectious diseases. The company recently began Phase 3 clinical development of teplizumab with its Protg study (http://www.protegediabetes.org) to evaluate the potential of the monoclonal antibody to treat patients with new-onset juvenile diabetes and Phase 1 clinical development of another antibody to treat West Nile virus infections. The company's proprietary Fc engineering technology offers means to improve antibody function, such as enhancing the antibody's ability to eliminate cancer cells, cells that contribute to autoimmune disorders, or those infected with certain pathogens. For more information about MacroGenics, please visit http://www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward- looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. WTN interview: Dr. Jeffrey Grossman, CEO UW Medical Foundation
2. Chemical-petroleum executive joins Virent Energy board
3. Schneider National exec joins TrafficCast board
4. Doyle joins governors in support of stem cell bill
5. Genomics researcher Hood joins NimbleGen board
6. Fergus joins Baird Venture Partners, Caden Bio
7. Meier joins Broadlook Technologies as COO
8. Prodesse joins forces with Invitrogen
9. Wisconsin joins price-fixing suit vs. D-RAM makers
10. Napier joins board of Third Wave Technologies
11. Schmidt rejoins Renaissance Learning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/22/2017)... , March 22, 2017 Regeneron Pharmaceuticals, Inc. ... Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate ... U.K. Biobank resource. The initiative will enable researchers to gain ... medicines for a wide range of serious and life threatening ... ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics ... ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
Breaking Biology News(10 mins):